EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY 4.0

Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network

Pauline Gandolfo, Thomas Soeiro iD, Élisabeth Jouve, Bruno Revol, Amélie Daveluy iD, Célian Bertin, Céline Eiden iD, Valérie Gibaja, Leila Chaouachi, Marie-Christine Pérault-Pochat, Cécile Chevallier, Aurélie Aquizérate and 6 more

Fundamental & Clinical Pharmacology · 2024

DOI: 10.1111/fcp.12995 ↗

At a glance

Multizentrische Studie in Fundamental & Clinical Pharmacology, 2024. Written by Pauline Gandolfo and 17 co-authors. Institution: U1106 Aix-Marseille Université, Inserm, Marseille, France. Major MEDLINE topics: Ketamine, Substance-Related Disorders, Pharmacovigilance, Databases, Factual. Cited 11 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Due to its psychoactive effects, ketamine has become a drug used for non‐medical purpose.

Objectives

To assess the latest trends in ketamine use among people with substance use disorder and to characterize its clinical complications using complementary health data sources of the French Addictovigilance Network.

Methods

First, we extracted all reports involving ketamine from 2012 to 2021 from the database of the OPPIDUM program (i.e., a multicentric program conducted in collaboration with hundreds of substance abuse treatment facilities that collects data on drugs used by subjects with substance use disorders). We described the reports globally and the changes from 2012 to 2021. Second, we extracted all cases involving ketamine from July 2020 to December 2022 from the French National Pharmacovigilance Database (BNPV). We identified the cases related to ketamine use among people with substance use disorder and described them.

Results

There was a 2.5‐fold increase in the number of ketamine users with substance use disorder in the OPPIDUM program, from 35 (0.7%) subjects in 2012 to 89 (1.7%) subjects in 2021. There was an increase in the proportion of subjects who were daily users, had distress upon discontinuation, and presented addiction. There were 238 cases related to ketamine use among people with substance use disorder in the French National Pharmacovigilance Database from July 2020 to December 2022. Among them, 94 (39.5%) cases involved ketamine use disorder, 20 (8.4%) cases involved urinary tract and kidney symptoms, and 13 (5.5%) cases involved hepatobiliary symptoms.

Conclusion

The trend observed over 10 years reflects the growth in ketamine use among people with substance use disorder, although it does not allow to estimate the rates of non‐medical use of ketamine in the general population. Ketamine‐induced uropathy and cholangiopathy are reported in ketamine users with substance use disorder, especially in case of repeated and/or prolonged use of high doses.

Subjects

MeSH terms (MEDLINE)

KetamineSubstance-Related DisordersPharmacovigilanceDatabases, FactualHumansFranceMaleAdultFemaleYoung AdultMiddle AgedAdolescent

Author keywords

addictovigilancedrug abuseketaminesubstance use disorder

Substances

Ketamine

Authors and institutions

  • U1106 Aix-Marseille Université, Inserm, Marseille, France.
  • Centre d'évaluation et d'information sur la pharmacodépendance - Addictovigilance, Service de pharmacologie clinique, Assistance Publique - Hôpitaux de Marseille, Marseille, France.
  • Centre d'évaluation et d'information sur la pharmacodépendance - Addictovigilance, Service de pharmacologie clinique, Centre hospitalier universitaire de Grenoble, Grenoble, France.
  • Centre d'évaluation et d'information sur la pharmacodépendance - Addictovigilance, Service de pharmacologie clinique, Centre hospitalier universitaire de Bordeaux, Bordeaux, France.
  • Centre d'évaluation et d'information sur la pharmacodépendance - Addictovigilance, Service de pharmacologie clinique, Centre hospitalier universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
  • Centre d'évaluation et d'information sur la pharmacodépendance - Addictovigilance, Service de pharmacologie clinique, Centre hospitalier universitaire de Montpellier, Montpellier, France.

ORCID profiles: Thomas Soeiro, Amélie Daveluy, Céline Eiden, Maryse Lapeyre-Mestre, Élisabeth Frauger, Joëlle Micallef

Cite

APA

Gandolfo, P., Soeiro, T., Jouve, É., Revol, B., Daveluy, A., Bertin, C., Eiden, C., Gibaja, V., Chaouachi, L., Pérault-Pochat, M. C., Chevallier, C., Aquizérate, A., Le Boisselier, R., Carton, L., Lapeyre-Mestre, M., Frauger, É., Lacroix, C., & Micallef, J. (2024). Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12995

Vancouver

Gandolfo P, Soeiro T, Jouve É, Revol B, Daveluy A, Bertin C, et al. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12995

BibTeX
@article{Gandolfo2024,
  author = {Gandolfo, Pauline and Soeiro, Thomas and Jouve, Élisabeth and Revol, Bruno and Daveluy, Amélie and Bertin, Célian and Eiden, Céline and Gibaja, Valérie and Chaouachi, Leila and Pérault-Pochat, Marie-Christine and Chevallier, Cécile and Aquizérate, Aurélie and Le Boisselier, Reynald and Carton, Louise and Lapeyre-Mestre, Maryse and Frauger, Élisabeth and Lacroix, Clémence and Micallef, Joëlle},
  title = {Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/fcp.12995}
}
Start for free →